2,049 results on '"sevelamer"'
Search Results
102. A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
103. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.
104. The Therapeutic Effects of Sevelamer on Blood Sugar, HbA1c, Lipid Profile, and hs-CRP in Patients with Diabetic Nephropathy
105. Sevelamer-Induced Gastrointestinal Injury Presenting as Gastroenteritis
106. Total and Individual Coronary Artery Calcium Scores as Independent Predictors of Mortality in Hemodialysis Patients
107. Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation.
108. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols
109. A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
110. Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
111. A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
112. The Effects of Sevelamer Carbonate on Diabetic Nephropathy
113. A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
114. Study of Phosphate Levels in Patients With Chronic Kidney Disease (PA21)
115. A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia (Sevelamer ECS)
116. Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
117. Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
118. Effects of Sevelamer and Calcium-Based Phosphate Binders on Lipid and Inflammatory Markers in Hemodialysis Patients
119. Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial
120. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure.
121. POOR NUTRITIONAL STATUS AND INFLAMMATION: Metabolic Acidosis and Malnutrition‐Inflammation Complex Syndrome in Chronic Renal Failure
122. Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis (Independent)
123. Drug treatment of phosphate-calcium metabolism disorders in patients with chronic kidney disease and mineral and bone disorder
124. A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
125. Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) (SIR)
126. A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)
127. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
128. Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
129. Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
130. Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
131. A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
132. Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review.
133. Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
134. Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease (SUMMER)
135. Regulation of Bone Formation in Renal Osteodystrophy
136. Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia (ACT3)
137. Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients.
138. Pathology of Resin-Induced Gastrointestinal Damage: Report of 15 Cases and Review of Literature.
139. An Unusual Combination of Neurological Manifestations and Sudden Vision Loss in a Child with Familial Hyperphosphatemic Tumoral Calcinosis.
140. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
141. Exploring co-dispensed drug use in patients on sevelamer or polystyrene sulfonate to identify potential novel binding interactions
142. Comparison of sevelamer and calcium carbonate in prevention of hypomagnesemia in hemodialysis patients
143. CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
144. Drug Crystal-Related Gastrointestinal Complications Involve Crystal-Induced Release of Neutrophil and Monocyte Extracellular Traps
145. Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD
146. Crystal-Associated Colitis with Ulceration Leading to Hematochezia and Abdominal Pain
147. Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
148. Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization
149. 'Fish-scales' and graft nephrectomy: unexpected findings at an unusual site
150. Systematic review and meta‐analysis of potential pleiotropic effects of sevelamer in chronic kidney disease: Beyond phosphate control
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.